FindTrial
Sign In

Efficacy and Safety of Early Neuromuscular Blocking Agent Therapy in Patients with Moderate to Severe ARDS: A Systematic Review

Efficacy and Safety of Early Neuromuscular Blocking Agent Therapy in Patients with Moderate to Severe ARDS: A Systematic Review - Efficacy and Safety of Early Neuromuscular Blocking Agent Therapy in Patients with Moderate to Severe ARDS: A Systematic Review

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000056205
Enrollment
Unknown
Registered
2024-11-20
Start date
2024-11-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome (ARDS)

Interventions

None listed

Sponsors

Fukuyama City Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients diagnosed with ARDS within 48 hours

Exclusion criteria

Exclusion criteria: Patients with a history of neuromuscular blocking agent use within the past 2 weeks. Patients with chronic respiratory failure.

Design outcomes

Primary

MeasureTime frame
To evaluate the efficacy of early neuromuscular blockade in reducing mortality among patients with moderate to severe ARDS, initiated within 48 hours of diagnosis.—

Secondary

MeasureTime frame
To determine whether the use of neuromuscular blocking agents in patients with moderate or severe ARDS, initiated within 48 hours of diagnosis, improves the quality of life (QOL) as measured by EQ-5D, reduces the incidence of pressure injuries, shortens the duration of mechanical ventilation, and decreases the occurrence of ICU-acquired weakness. A subgroup analysis will compare studies where the control group received deep sedation versus light sedation.—

Countries

Japan

Contacts

Public ContactKenzo Ishii

Fukuyama City Hospital Department of Anesthesiology, Intensive Care Unit

keishii1101@gmail.com0849415151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026